Non-MRI biomarkers should be accepted to guide treatment escalation in MS: Yes
Multiple Sclerosis Journal · 29.04.2026
DOI: 10.1177/13524585261439622 ↗Kurz gefasst
Fachartikel in der Zeitschrift Multiple Sclerosis Journal, online erschienen am 29.04.2026. Verfasst von Adrian-Minh Schumacher und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlan…. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: universität zürich, Michael J. Fox Foundation for Parkinson’s Research, Nederlandse Organisatie voor Wetenschappelijk Onderzoek.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Laboratory Medicine, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
ORCID-Profile: Adrian-Minh Schumacher, Charlotte E Teunissen
Förderung
- universität zürich
- Michael J. Fox Foundation for Parkinson’s Research
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- AlzheimerDrug Discovery Foundation
- Selfridges Group Foundation
- Innovative Medicines Initiative
- Health Holland
- European Partnership on Metrology
Zitieren
APA
Schumacher, A. M., & Teunissen, C. E. (2026). Non-MRI biomarkers should be accepted to guide treatment escalation in MS: Yes. Multiple Sclerosis Journal. https://doi.org/10.1177/13524585261439622
Vancouver
Schumacher AM, Teunissen CE. Non-MRI biomarkers should be accepted to guide treatment escalation in MS: Yes. Multiple Sclerosis Journal. 2026. doi:10.1177/13524585261439622
BibTeX
@article{Schumacher2026,
author = {Schumacher, Adrian-Minh and Teunissen, Charlotte E},
title = {Non-MRI biomarkers should be accepted to guide treatment escalation in MS: Yes},
journal = {Multiple Sclerosis Journal},
year = {2026},
doi = {10.1177/13524585261439622}
}
EUVIMED